Search
Menu
Home
Sources
About
Contacts
DSP-2230
DSP-2230
is a
selective
small-molecule
Na
v
1.7 and Na
v
1.8
voltage-gated sodium channel
blocker
which is
under development
by
Dainippon Sumitomo Pharma
for the
treatment
of
neuropathic pain
. As of
June 2014
, it is
in phase
I/phase
II
clinical trials
.